For research use only. Not for therapeutic Use.
Octreotide acetate (Cat No.: I008400) is a synthetic somatostatin analog used to treat hormone-secreting tumors, acromegaly, and gastrointestinal disorders. It inhibits the release of growth hormone, insulin, glucagon, and other peptides, making it effective for conditions like carcinoid syndrome and VIPomas. With a longer half-life than natural somatostatin, it provides sustained therapeutic effects. Octreotide acetate is also used in research and clinical settings to manage severe diarrhea, bleeding varices, and endocrine disorders, offering targeted symptom relief in various metabolic and oncological diseases.
| CAS Number | 79517-01-4 (acetate); 83150-76-9 (free base). |
| Synonyms | Longastatin; Sandostatin; Longastatina; Samilstin; Sandostatina; Sandostatine; SMS 201995;1-((4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-4-(((2R,3R)-1,3-dihydroxybutan-2-yl)carba |
| Molecular Formula | C55H76N10O15S2 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide |
| InChI | 1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1 |
| InChIKey | DEQANNDTNATYII-OULOTJBUSA-N |
| SMILES | C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O |
| Reference | </br>1:[The Use of Octreotide Acetate in the Management of Refractory Chylothorax Following Surgical Treatment for Lung Cancer]. Kawakami T, Ishida I, Sugawara T, Oura H.Kyobu Geka. 2016 Jun;69(6):429-32. Japanese. PMID: 27246125 </br>2:Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. Kim S, Hosoya K, Takagi S, Okumura M.J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12. doi: 10.5326/JAAHA-MS-6270. PMID: 26535461 </br>3:A rapid hydrolysis method and DABS-Cl derivatization for complete amino acid analysis of octreotide acetate by reversed phase HPLC. Akhlaghi Y, Ghaffari S, Attar H, Alamir Hoor A.Amino Acids. 2015 Nov;47(11):2255-63. doi: 10.1007/s00726-015-1999-9. Epub 2015 May 23. PMID: 26002809 </br>4:Stability of octreotide acetate decreases in a sodium bisulfate concentration-dependent manner: compatibility study with morphine and metoclopramide injections. Tanabe K, Wada J, Ohkubo J, Nitta A, Ikezaki T, Takeuchi M, Handa A, Tanaka M, Murakami N, Kashii T, Kitazawa H.Eur J Hosp Pharm Sci Pract. 2015 May;22(3):171-175. Epub 2015 Jan 16. PMID: 25984298 Free PMC Article</br>5:[Successful treatment of a case of chylothorax, manifesting as a complication following surgical treatment of coarctation of the aorta, by using octreotide acetate; report of a case]. Matsushita H, Hanayama N.Kyobu Geka. 2014 Feb;67(2):149-52. Japanese. PMID: 24743487 </br>6:Octreotide acetate-steroid combination therapy for malignant gastrointestinal obstruction. Murakami H, Matsumoto H, Nakamura M, Hirai T, Yamaguchi Y.Anticancer Res. 2013 Dec;33(12):5557-60. PMID: 24324097 </br>7:Octreotide acetate administration for malignant bowel obstruction induces severe bradycardia in patients with terminal stage cancer: two case reports. Kubota K, Hasumi Y, Numata A, Tukazaki T, Horie K, Hashimoto K, Yokota H.J Palliat Med. 2013 Jun;16(6):596-7. doi: 10.1089/jpm.2012.0564. Epub 2013 Apr 21. No abstract available. PMID: 23600413 </br>8:Hypercalcemia appeared in a patient with glucagonoma treated with octreotide acetate long-acting release. Rui M, Li L, Jiang-Feng M, Feng G, Hui-Juan Z, Wen-Hui L, Yu-Xiu L.Chin Med Sci J. 2012 Sep;27(3):182-4. PMID: 23062642 </br>9:[Postoperative refractory chylothorax which was improved by octreotide acetate]. Gabe A, Seki M, Taira N, Katsura M, Ishida T, Kang Y, Kubota T, Yamashiro T, Uehara T, Sunagawa T, Ohkubo K.Kyobu Geka. 2012 Mar;65(3):230-3. Japanese. PMID: 22374601 </br>10:Resolution of a posttraumatic pancreatic pseudocyst with octreotide acetate in a pediatric patient. Wensil AM, Balasubramanian SA, Bell TL.Pharmacotherapy. 2011 Sep;31(9):924. doi: 10.1592/phco.31.9.924. PMID: 21923595 |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
; 83150-76-9 (free base)..gif)